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However, the use of clofibrate (a PPARa
agonist no longer available in the United
States) was associated with increased
total mortality due in part to an increased
rate of cancer (Committee of Principal
Investigators, 1984).
So is PPARa a savior or a savage? It
can probably be both, depending on the
degree and site of activation. PPARs are
versatile proteins with effects that
depend on ligand kinetics, the stoichiom-
etry of available coactivators, and com-
petition with other factors such as re-
pressors. The pleiotropic effects of
PPARa could help explain why a recent
large fenofibrate clinical trial, the Fenofi-
brate Intervention and Event Lowering in
Diabetes (FIELD) study, yielded mixed
benefits (http://www.americanheart.org/
presenter.jhtml?identifier=3035469). By
defining a role for PPARa in the control
of smoothmuscle cell-cycle progression,
Gizard and colleagues have extended
our understanding of the complex events
mediated by this nuclear receptor. Their
findings also raise the possibility that lo-
cal delivery of PPARa activators to sites
of vascular disease could be an ideal
way to save tissues at risk for vascular
disease without savaging other tissues
like the liver.
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PPARα
• Improves lipid metabolism 
• Induces peroxisomal proliferation
• Hepatic dysfunction?
Net beneficial effect? 
• Induces p16
• Decreases SMC proliferation
• Decreases restenosis?
  atherosclerosis?  
VasculatureLiver
Figure 1. An unexpected process mediated by PPARa
Activation of the nuclear receptor PPARa by fibrate drugs is known to improve systemic lipid metabolism
through events occurring predominantly in the liver. Activation of hepatic PPARa can also cause peroxisomal
proliferation, liver dysfunction, and tumors (especially in rodents). Recent findings by Gizard and colleagues
show that activation of PPARa in vascular smooth muscle cells surprisingly induces the tumor suppressor
p16 and decreases smooth muscle proliferation, suggesting a potentially novel strategy for treating restenosis
and atherosclerosis.
P R E V I E W SCollecting new targets in MODY
Transcriptional regulation is crucial in the function of the pancreatic b cell and diabetes, as evidenced by the human MODY
families. Work from Fukui and colleagues (Fukui et al., 2005) and Akpinar and colleagues (Akpinar et al., 2005) in this issue of
Cell Metabolism identifies a target of the MODY3 transcription factor HNF-1a that appears to function both in insulin secre-
tion and b cell proliferation.Although maturity onset diabetes of the
young, or MODY, comprises only a small
proportion of all patients with diabetes, it342has been extremely useful in elucidating
the genetic causes and molecular etiol-
ogy of diabetes. MODY was originallydesignated by Tattersall and Fajans
(Tattersall and Fajans, 1975), who de-
scribed the first families with monogenicCELL METABOLISM : DECEMBER 2005
P R E V I E W Sdiabetes. MODY is characterized by an
autosomal dominant mode of inheritance
and onset before the age of 25. To date,
sixMODYgenes have been identified (re-
viewed in Shih and Stoffel, 2002).
MODY2 encodes glucokinase, the rate
limiting step for glucose metabolism in
the pancreatic b cells and liver. Strikingly,
the other five MODY genes encode
transcription factors: HNF4a [MODY1];
HNF1a [MODY3]; IPF-1 [MODY4]; HNF1b
[MODY5]; and neurogenic differentiation
factor 1 (NeuroD1) [MODY6], highlighting
the importance of transcriptional net-
works in b cell function. Work from two
groups, published in this issue of Cell
Metabolism, has identified Tmem27 (col-
lectrin) as a HNF-1a target that plays
a key role in b cell function.
Although the relative frequency of the
MODYmutations in the population varies
dramatically, with MODY3 being the
most abundant, the penetrance of the
phenotype is very high for all known mu-
tations (Froguel and Velho, 1999).Two
mouse models have been derived in or-
der to further our understanding of the
molecular and physiological analysis of
MODY3: mice completely devoid of
HNF-1a (also known as Tcf1) function
(HNF-1a2/2 mice), and transgenic mice
expressing a dominant-negative form of
HNF-1a in pancreatic b cells (Pontoglio
et al., 1996; Yamagata et al., 2002).
HNF-1a-deficient islets display a dra-
matic impairment in stimulus secretion
coupling, a phenotype that has been as-
cribed to defects in glycolysis (Dukes
et al., 1998; Pontoglio et al., 1996; Ponto-
glio et al., 1998; Yamagata et al., 2002).
Overexpression of a dominant-negative
form of HNF-1a in transgenic mice also
causes diabetes, however, this model is
characterized by a loss of b cell mass
and altered islet structure. Inducible ex-
pression of the same dominant-negative
HNF-1amutant in INS-1 insulinoma cells
has also been exploited to identify glyco-
lytic andmitochondrial enzymes as HNF-
1a targets (Wang et al., 2000). However,
it is not clear whether the known HNF-
1a targets explain the full spectrum of
disease phenotypes found in MODY3.
The two studies published in this issue
of Cell Metabolism employ unbiased ge-
nome-wide approaches to identify addi-
tional targets of HNF-1a that might have
an important function in b cell biology
(Akpinar et al., 2005; Fukui et al., 2005).
While Akpinar and colleagues utilized
expression profiling of HNF-1a2/2 islets,CELL METABOLISM : DECEMBER 2005aC +2
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Figure 1. Model for the potential roles of the HNF-1a target Tmem27, also known as ‘‘collectrin,’’ in the pro-
motion of insulin exocytosis in pancreatic b cells and b cell proliferation
After glucose enters the b cell through the facilitative glucose transporter GLUT2, it is metabolized by glycol-
ysis and oxidative phosphorylation to raise the cytoplasmic ATP to ADP ratio. This is followed by closure of the
ATP-dependent potassium channel, depolarization of the plasma membrane, and Ca2+ influx. In the nucleus,
HNF-1a is required for the transcriptional activation of Tmem27, which acts in promoting the docking of insulin
secretory vesicles through interaction with the SNARE complex, thus facilitating insulin secretion in response
to Ca2+ influx. The second mechanism of action proposed for Tmem27 is as a promoter of cellular proliferation
of b cells through an as yet unknown mechanism.Fukui and colleagues used suppression
subtraction on the INS-1 cell line ex-
pressing the dominant-negative mutant
of HNF-1a to identify their candidate
genes. In a satisfying convergence of
functional genomics approaches, both
laboratories identified Tmem27, formerly
known as Collectrin, as a genewhose ex-
pression is critically dependent on HNF-
1a in pancreatic b cells. Tmem27 is a gly-
coprotein that is partly homologous
to the C terminus of the angiotensin-
converting enzyme-related carboxypep-
tidase (ACE2). In congruent data from
both laboratories, Tmem27 expression
was confirmed to be dramatically re-
duced in HNF-1a2/2 islets, and was
shown to be a direct HNF-1a target by
promoter analysis and co-transfection
experiments. Expression of Tmem27 at
or near the cell surface was confirmed
by both groups by immunostaining.
However, beyond this, the results re-
ported by the two groups are strikingly
divergent, indicating that Tmem27 might
have multiple functions in b cells.
Fukui and colleagues focus on the
function of Tmem27 in insulin secretion.
Through overexpression of Tmem27 in
INS-1 insulinoma cells or in b cells intransgenic mice in vivo, they demon-
strate that Tmem27 stimulates insulin
secretion by the b cell downstream of
Ca2+ influx (see Figure 1). Tmem27 was
localized to the limiting membrane of
secretory vesicles by immuno-electron
microscopy. They show further that
Tmem27 can bind to the SNARE com-
plex, themediator of exocytosis, by inter-
acting with snapin, providing a molecular
explanation for their discovery. Notably,
in their transgenic lines which elevate
Tmem27 protein levels about 2-fold,
there was no difference in islet morphol-
ogy or b cell mass.
The findings by Akpinar et al. on
Tmem27 function are almost completely
opposite. In their transgenic mice with
approximately 4-fold overexpression
of Tmem27, glucose-stimulated insulin
secretion is identical to non-transgenic
controls. Instead, they observe a dra-
matic increase in b cell mass and insulin
content in these animals, suggesting
a role for this HNF-1a target in b cell pro-
liferation. This notion is supported by
their findings that insulinoma cell prolifer-
ation is impaired by inhibition of Tmem27
expression via siRNA, and stimulated by
Tmem27 overexpression. Akpinar and343
P R E V I E W Scolleagues also provide evidence that
the N-terminal portion of Tmem27 can
be cleaved and shed from b cells. How-
ever, this shed fragment showed no bio-
logical activity, and the authors conclude
that the full-length version of Tmem27
is responsible for cellular proliferation
through either a cell-autonomous or cell-
cell-signaling effect.
The divergent conclusions drawn on
the function of Tmem27 by the two labo-
ratories are difficult to reconcile at pres-
ent. This is true especially for the obser-
vations made on the transgenic mouse
models, which in both cases utilize the
rat insulin promoter to direct overexpres-
sion of Tmem27 to the pancreatic b cell.
One possibility for the different pheno-
types of the two mouse models is
the level of overexpression achieved,
which is two- versus 4-fold. Another
possibility to consider is that of trans-
gene integration site effects. During the
establishment of a transgenic mouse
line, the transgene integrates, often as
a concatamer of multiple copies, ran-
domly into the genome. On a rare occa-
sion, this integration disrupts the function
of another gene, causing a phenotype.
Finally, strain differences can also affect
the outcome of transgenic mouse experi-Osteoprotegerin, the
surprising target for
Osteoblasts influence bone mass by the
grade bone. In the December issue of De
expression of the osteoclast inhibitor, o
As baby boomers age, they face many
challenges: increasing health insurance
costs, diabetes, the metabolic syn-
drome, Alzheimer’s, and the increasing
risk of fracture because of thinning
bones. Congress, recognizing the need
to investigate the molecular mechanisms
regulating the function of bone cells, de-
clared a decade of bone and joint re-
search starting in 2002. This has yielded
enormous success, with major advances
in the understanding of how the skeleton
and bone cells are formed and how bone
is remodeled (renewed) in adult life. This
is exemplified by findings reported earlier
this year indicating that Wnt signaling not
only determines if mesenchymal progen-
344ments. Clearly, a lot more work is re-
quired to reconcile these differences
and to establish which mechanism of ac-
tion of Tmem27 is the predominant one.
In summary, it is clear that Tmem27
is a novel and direct target of the
MODY3 gene HNF-1a in pancreatic
b cells, which has dramatic effects on
b cell function. The final evaluation of its
molecular mechanism of action will re-
quire studies in mice with targeted abla-
tion of this gene. Regardless of the con-
troversy surrounding the function of
Tmem27, it is an exciting potential phar-
macological target for the treatment of
type 2 diabetes.
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bone remodeling. Osteoblasts orches-
trate bone destruction by expressing Re-
ceptor Activator of NF-kB (RANK) ligand
in response to osteoclast-stimulating
hormones and cytokines, such as PTH,
TNF, and IL-1, but they also protect the
skeleton by secreting osteoprotegerin
(OPG) (Simonet et al., 1997). RANKL
binds to its receptor, RANK, on osteo-
clast precursors to mediate osteoclast
differentiation and subsequent activa-
tion; osteoprotegerin, a secreted nonsig-
naling decoy receptor for RANKL, inhibits
both physiological and pathological bone
resorption. Surprisingly, Opg expression
was found to be regulated by b-catenin
signaling through TCF1 (Glass et al.,
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